Board of Directors

Eric N. Valor

Mr. Valor is a celebrated patient-advocate in the ALS community. He was presented with ALS-TDI’s 2010 Stephen Milne Award for his leadership in conducting thorough independent research and sharing it with the community. After a 20 year career in information technology building technology development start-ups, he retired as the Information Technology Operations Manager for Mercedes-Benz Research & Technology, North America. He now consults for non-profit and commercial development programs in ALS. He is recognized in the open-science space for his initiatives to utilize patient-driven studies in the
determination of therapeutic benefit.

Andrew Gengos

Mr. Gengos is also currently President, Chief Executive Officer and as a director of ImmunoCellular Therapeutics. He was previously President and Chief Executive Officer of Neuraltus Pharmaceuticals, where he led implementation of the company’s clinical, regulatory, fundraising and business development strategies while operating the company on a virtual business model. Previously, he served with Amgen where, as Vice President, Strategy and Corporate Development. Before joining Amgen, Mr. Gengos was Vice President, Chief Financial Officer, and Chief Business Officer of Dynavax Technologies. Earlier in his career, Mr. Gengos served as Vice President of Strategy at the Chiron Corporation and as Senior Engagement Manager at McKinsey & Company. Mr. Gengos holds an MBA degree from the Anderson School of Management at the University of California, Los Angeles and a BS degree in chemical engineering from the Massachusetts Institute of

Ryan Bethencourt

Ryan Bethencourt serves concurrently with ICON Clinical Research (PhIb-IV) in 2012 as Director of Business Development with responsibilities for managing business and corporate development functions and establishing strategic clinical collaborations in the San Francisco Bay area and Pacific Northwest. Mr. Bethencourt has over a decade of Biopharma experience, including seven years of Clinical Development experience with PAREXEL as Director of Business Development for the West coast, and at Quintiles as the European Business Development Manager, conducting a broad range of translational clinical development studies. Earlier in his career, Ryan worked in a variety of sales and business development roles within Pfizer, Merck and Cephalon. Ryan received a Master’s in Bioscience Enterprise from the University of Cambridge and a BS degree in Biology and Genetics from the University of Warwick. Ryan is also a published author in the field of Biotechnology Business Development and is involved with start-up Biotech ventures.

Joseph Jackson

Joseph Jackson is a longtime advocate and leader of the Open Science and Citizen Science movements. He began by developing the Lava Amp pocket Polymerase Chain Reaction unit for DNA diagnostics and research. He was a co-founder of BioCurious, the first San Francisco Bay Area hacker biotechnology lab. Since 2006, Mr. Jackson is the founder and organizer of the Open Science Summit, the annual gathering of Open Science advocates and researchers, dedicated to the future of collaborative science. Currently he is also co-founder of Bio, Tech & Beyond in Carlsbad, California.

Mike Shannon

Mike Shannon is a member of the ALS community as a development consultant, ambassador, and advocate for PALS. He provides support and perspective in the area of drug development, patient care issues, and advocacy to many ALS organizations. He is also personally actively involved with individual PALS on specific projects. For 7 years, Mike served as Western Regional Director for the ALS Therapy Development Institute. With 10 years of experience in the ALS community, he has a fluent understanding of the challenges in biomedical research, the obstacles to rapid drug development, and the critical desires and needs of PALS. Mike resides in Spokane, Washington and also works for Team Gleason and Answer ALS in the Northwest.

Home of the world's first fully-functional guerrilla biotech